Glideslope AI-powered market news
1 stories in the last 7 days, reading neutral overall. Quiet in the last 24 hours.
| Day | Mood | Stories |
|---|---|---|
| Sat, Oct 10 | — | 0 |
| Fri, Oct 9 | — | 0 |
| Thu, Oct 8 | — | 0 |
| Wed, Oct 7 | — | 0 |
| Tue, Oct 6 | — | 0 |
| Mon, Oct 5 | — | 0 |
| Sun, Oct 4 | +11.8 | 1 |
| Sat, Oct 3 | — | 0 |
One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice comes down to whether you prioriti…
Plus, Turner delivers a $29 million substance use treatment center, CMAA names a new CEO and a British engineering firm crosses the pond.
The practice of editing the genes of embryos remains highly controversial and risky, but Origin Genomics founder Cathy Tie argues its a "moral imperative" to a…
Analyst Geoff Meacham downgraded the biotech name to sell.
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
One fund offers broad sector exposure at 0.08% cost; the other concentrates on 30 biotech stocks with higher volatility but stronger recent returns.
"Why would I deceive you? There's no reason for me to do that," an unblinking, wild-eyed Elizabeth Holmes said.
The personal investment firms of titans like Stanley Druckenmiller are backing innovations in gene editing, drug discovery and more.
For developers, the operating assumption has been one engineer, one agent - the model Claude Code and similar tools. At VB Transform 2026, James Zou, associate…
The healthcare subsector has quietly become one of the most attractive opportunities this year.
One offers broad stability with lower costs and higher income, while the other chases biotech growth with 89.3% annual returns but steeper volatility.
Analyst Faisal Khurshid upgraded the stock to buy from hold.
Shares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug for bowel disease.
AbbVie is reportedly trying to buy a biotech company that is developing a promising atopic dermatitis drug for $10.9 billion in cash, according to a Financial…
While the market's enthusiasm for one of Zealand's experimental drugs has cooled, investors are shifting focus to amylin-based medicines as a growth driver
Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.
Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.
It's not the news that AbbVie needed, given the challenging year it is having.
It's a well-known and almost quaint fact that the human body is capable of regeneration. When we suffer a minor scrape or a cut, a little disinfectant, a band-…
The investment bank upgraded the pharma stock to overweight from equal weight.
Companies have long lamented Europe's fragmented capital markets, single-market adoption on pricing and clinical trials, and uneven reimbursement policies.
Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, according to The Information and Eric Newcomer.
The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than anything currently on the market.
Federal health officials have issued a warning about controversial statements made by biotech billionaire Dr. Patrick Soon-Shiong about one of his company's ca…
NovaBay Pharmaceuticals was founded in 2000 as a biopharmaceutical company developing eye care products and is now betting big on the Sky protocol and stableco…
This experimental pill helped people lose about 16% of their body weight after about a year of treatment
The bank initiated the clinical-stage biotechnology firm at a buy rating.
Josh Brown and Sean Russo take a look at the biotech stocks in their Best Stocks list.
Vinay Prasad, an official for the Food and Drug Administration, is reportedly stepping down, which is welcome news for biotech companies.
Shares of biotech company CSL plunged after the company announced that Chief Executive Officer Paul McKenzie will step down.
Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE